JOHNSON & JOHNSON is 74.6x more valuable than Abivax S.A. by market capitalization ($573.98 B vs $7.70 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ABVX | JNJ |
|---|---|---|
| Market cap | $7.70 B | $573.98 B |
| US-listed rank | #1093 | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | - | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 92 | 984 |
JOHNSON & JOHNSON is 74.6x more valuable than Abivax S.A. by market capitalization ($573.98 B vs $7.70 B).
Full pages: Abivax S.A. and JOHNSON & JOHNSON, or browse the full rankings.